ABSTRACT
I. ABSTRACT All three of the major female cancers (breast, endometrium, and ovary) have been demonstrated to be preventable-i.e., their incidence can be significantly reduced by a hormonal chemopreventive approach. Oral contraceptive (OC) use significantly reduces the incidence of both ovarian and endometrial cancer, and use of the SERM tamoxifen has been shown to yield an equally impressive reduction in the incidence of breast cancer. The task now is to work out how best to combine these chemopreventive approaches to maximize the benefits and reduce the risks associated with their use.
